LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

DOI Web Site Web Site 被引用文献1件

収録刊行物

  • The Lancet

    The Lancet 400 (10366), 1869-1881, 2022-11

    Elsevier BV

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ